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ABSTrACT
Sialorrhea or excessive salivation, and drooling, are common and disabling manifestations in different neurological 
disorders. A review is made of the literature, based on a PubMed search, selecting those articles describing clinical trials 
involving the injection of botulinum toxin A in the salivary glands of patients with different diseases characterized by 
sialorrhea.
The most frequently treated diseases were infant cerebral palsy (30%), Parkinson’s disease (20%) and amyotrophic lateral 
sclerosis (15%). Over half  of the authors injected the product into the parotid glands, 9.5% into the submaxillary glands, 
and 38% into both. The total doses of toxin injected varied from 10-100 units of Botox® or 30-450 units of Dysport® 
according to the different authors. A reduction was observed in the production of saliva following these injections, and 
the duration of the therapeutic effect was 1.5-6 months. Six articles (30%) described the presence of adverse effects such 
as dysphagia, xerostomia and chewing difficulties.
Most of the clinical studies involved small patient samples, with no blinding or randomization, and no control group. 
Moreover, no data are available on the efficacy and adverse effects of treatment in the context of long-term prospective 
studies. The effective therapeutic dose and ideal form of application remain to be established, and require the conduc-
tion of further controlled clinical trials involving large sample sizes.
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INTrODUCTION
Sialorrhea or excessive salivation, and drooling, are com-
mon and disabling manifestations in different neurological 
disorders (1) such as amyotrophic lateral sclerosis (ALS) or 
Parkinson’s disease, and often coincide with alterations in 
swallowing reflex (2).
Drug substances are an option (though not the only pos-
sibility) for the treatment of  sialorrhea. Anticholinergic 
agents are the basic options in pharmacotherapy, and 
include glycopyrrolate, propantheline and scopolamine. 
These anticholinergic drugs reduce the volume of saliva as 
a result of reversible muscarinic cholinergic receptor block 
(specifically the M3 receptors). However, undesirable adver-
se effects are often observed with such treatment, including 
constipation, urinary retention, tiredness, irritability and 
drowsiness (3-4).
Other therapeutic options include surgery, irradiation, 
“biofeedback” measures, positional techniques and oral 
motor or behavioral therapy (exercises to improve the oral 
musculature) (3).
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CONCEPT
Neurobotulinum toxin serotype A (TBA) has drastically 
changed the treatment of a broad range of autonomous hy-
persecretory alterations such as focal hyperhidrosis (axillary 
perspiration, sweating of the palms, or gustative perspira-
tion), sialorrhea, pathological lacrimation, and rhinorrhea 
(5). Its application as treatment for sialorrhea was first 
proposed in 1997 by Bushara, in the form of an injection 
into the parotid glands of patients with amyotrophic lateral 
sclerosis and other neurological diseases (1). This toxin is 
produced by a gramnegative anaerobic bacterium, Clostri-
dium botulinum (2). Its action is based on the inhibition of 
acetylcholine release at presynaptic level (1). The toxin acts 
upon the cholinergic nerve endings, causing proteolysis of 
SNAP-25 (synaptosomal associated protein, implicated in 
synaptic vesicle fusion with the presynaptic membrane)(1,5), 
thus resulting in local chemical denervation and the loss of 
neuronal activity in the target organ.
Two TBA formulations can be found on the market: Dys-
port® (Speywood Pharmaceuticals Ltd, Maidenhead, UK) 
and Botox® (Allergan Inc., Irvine, USA). It is estimated 
that one unit of Botox® is equivalent to 3 or 4 units of 
Dysport® (2).
The present study reviews the scientific literature on the in-
jection of TBA into the human salivary glands, as palliative 
treatment for sialorrhea.
A Medline/PubMed search was conducted, covering the 
period between January to October 2005. The search was 
limited to articles published in English, French, German 
and Spanish. The key words used included sialorrhea, 
botulinum toxin, Botox® and hypersalivation. We selected 
those articles that involved the injection of botulinum toxin 
into the salivary glands as sole treatment in patients with 
sialorrhea.
A total of 21 articles were considered valid. The predomi-
nant treated pathologies characterized by sialorrhea were 
infant cerebral palsy (6 articles)(6-11), Parkinson’s disease 
(4 articles)(12-15), and amyotrophic lateral sclerosis (2 
articles)(16-18)(Table 1) - though such treatment has also 
been used in different ear, nose and throat problems (2 ar-
ticles)(19-20), and in other pathologies (18,21-26)(Table 2). 
Of the total publications reviewed, only three corresponded 
to controlled clinical trials (11,14,26).
Over half  of these studies were published in neurological 
journals (12-18,22,23,25,26), four in ear, nose and throat 
publications (10,19-21), three in neuropediatric journals 
(7-9), two in pediatric publications (6,11), and one in an 
oral and maxillofacial surgery journal (27).
Most of  the authors describe injection into the parotid 
glands (50%)(1,8,12,13,15,17,22, 23,25,26), with a lesser 
percentage into the submaxillary glands (10%)(6,10,11). 
In turn, 40% inject the toxin into both gland locations 
(40%)(10,14,16,18-20,27).
In 11% of  these studies (6,10,11,14,15,18,20,21,27), in-
jection of the toxin was intraglandular under ultrasound 
guidance.
The total doses of toxin injected varied from 10-100 units 
of Botox® or 30-450 units of Dysport®, and the duration 
of the therapeutic effect was 1.5-6 months.
On the other hand, different adverse effects were reported 
in 7 of  the articles (30%), including dysphagia (22), dry 
mouth (15, 18, 22), chewing difficulty (22), and even a case 
of recurrent mandibular luxation (17).
BOTULINUM TOXIN IN CErEBrAL PALSY 
PATIENTS
Jongerius et al. (6) treated three children with the injection 
of TBA in both submaxillary glands, at two points in each 
gland, under ultrasound guidance with general anesthesia 
- delivering a total of 40 to 50 U of Botox® according to 
body weight. Salivation was assessed by quantitative sialo-
metry based on the weight of cotton rolls, and applying a 
test to the parents. In two weeks a reduction in salivation 
weight of 51-63% was recorded for a variable time period 
of 4-7 months during which no adverse effects were recor-
ded. Three years later, the same authors (11) conducted the 
first controlled clinical study comparing the efficacy of two 
different anticholinergic agents: bilateral TBA injections 
(a total of 30-50 U of Botox®) in the submaxillary glands, 
and the administration of transdermal patch scopolamine 
- using the salivation ratio (estimated percentage of  the 
ratio between the observed drooling episodes and the total 
number of  observations), severity scales and frequency 
of salivation, and a visual analog scale (VAS) as methods 
of  measurement. The first treatment option yielded a 
maximum effect 2-8 weeks after injection, and fewer and 
less important adverse effects were recorded than with the 
administration of scopolamine.
Bothwell et al. (8) injected the toxin into the parotid glands 
(5 U in each gland), following the application of a local 
anesthetic cream (Emla®) one hour before. They recorded 
a lesser duration of the therapeutic effect, equivalent to 
2-4 months in 55% of the sample, which was composed 
of  9 children aged between 14 and 17 years. Salivation 
was measured calculating the salivation ratio, the weight 
of  the Kleenex® used to dry drooling, and the salivary 
frequency and severity scales. Unlike these authors, Ellies 
et al. (9) infiltrated both parotid glands (22.5 U of Botox® 
per gland) and the submaxillary glands (10 U per gland), 
under ultrasound guidance in five children, and measuring 
salivation via quantitative and qualitative sialometry. The 
resulting reduction in drooling lasted about three months. 
The duration in turn was from two weeks to six months in 
a larger sample (n=22) divided into two groups reported by 
Suskind and Tilton (10). One group (n=12) was injected with 
a total of 10-30 U of Botox® in the submaxillary glands 
only, while the other group (n=10) received infiltration of 
the submaxillary glands at a total dose of 30 U, and of the 
parotid glands at a total dose of 20-40 U.
BOTULINUM TOXIN IN PATIENTS WITH AM-
YOTrOPHIC LATErAL SCLErOSIS (ALS)
Giess et al. (16) confirmed the adequacy of the approach 
adopted by Bushara (1), since they infiltrated both parotids 
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Table 1. Different studies on the application of TBA for the treatment of sialorrhea on patients with cerebral palsy, amyotrophic lateral sclerosis and 
Parkinson’s disease. TBA: botulinum toxin A. US: ultrasound. VAS: visual analog scale.
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with a total of 30-72 U of Botox® (mean 46 U) in 5 patients 
- supplementing this amount with 5 U per submaxillary 
gland if  the previous injection proved ineffective. No system 
was used for locating the glands, though the authors des-
cribed three points of infiltration for the parotids: cranial, 
ventral and caudad. They observed a marked reduction in 
sialorrhea in three of the patients, with a minimum duration 
of three months, and stressed the improvement in quality 
of life and the absence of dry mouth or the aggravation of 
dysphagia in their patients.
In 10 patients with different chronic neurological patholo-
gies, including four cases of ALS, Porta et al. (18) treated sia-
lorrhea with simultaneous intraparotid and submandibular 
gland injections, under ultrasound guidance in all cases. The 
doses administered in each parotid gland ranged from 15-40 
U of Botox® (mean 27.7 U) at points per gland. The doses 
injected into the submandibular glands corresponded to 10-
15 U of Botox® (mean 11.9 U). The total dose per patient 
ranged from 50-100 U (mean 76.6 U) according to body 
weight. The only patient that failed to improve significantly 
presented a bulbar form of ALS, and received the maximum 
dose corresponding to 40 U of Botox® per parotid gland 
and 10 U per submandibular gland. In the rest of cases a 
reduction of salivation was observed that persisted for 4-7 
months (mean 4.7 months).
A case has been published (17) of recurrent mandibular 
luxation following bilateral injections of  TBA into the 
parenchyma of both parotid glands (specifically, 5 U of 
Dysport® per gland in a first phase, and 10 U per gland in 
a second stage), with the purpose of treating sialorrhea in 
a 76-year-old woman diagnosed with ALS. The injection 
technique was based on manual palpation of the portion of 
the parotid gland located between the ascending mandibular 
ramus and the mastoid process. No side effects such as 
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Table 2. Different studies on the application of TBA for the treatment of sialorrhea on patients with neurodegenerative diseases, idiopathic hypersaliva-
tion and head and neck carcinoma. TBA: botulinum toxin A. US: ultrasound. MCV: mean corpuscular volume. VAS: visual analog scale.
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mandibular weakness were observed after administration, 
though two months later the patient reported sudden inabili-
ty to close the mouth, with associated mandibular pain. The 
patient had no antecedents of temporomandibular trauma 
or pathology. Clinical examination confirmed bilateral luxa-
tion of the mandible, which was manually reduced - though 
posteriorly the patient suffered spontaneous recurrences of 
luxation.
BOTULINUM TOXIN IN PATIENTS WITH 
PArKINSON’S DISEASE
Pal et al. (12) described the injection of TBA in the parotid 
glands of 9 patients with Parkinson’s disease. In coincidence 
with Bushara (1), ultrasound guidance was not used. Two 
points of  injection were considered: lower, between the 
mastoid process and the lower part of the vertical ramus of 
the mandible (5 U of Botox®); and a second upper point 
with respect to the posterior margin of the masseter muscle 
(2.5 U of Botox®), corresponding to a total dose of 7.5-15 
U of Botox® per gland. A positive effect was recorded in 6 
of the patients, though its duration was not specified. More 
recently, 11 patients were treated with the same injection te-
chnique (1,13,28), administering 5 U of Botox® per parotid 
gland. A quantitative analysis of sialorrhea was made, and 
the duration of the effect was about 6 weeks.
Mancini et al. (14) conducted a double blind placebo-control 
study in a sample of 20 patients. One-half  were injected 
with 450 U of Dysport®, while the other half  received 2 ml 
of placebo in the parotid and submaxillary glands, under 
ultrasound guidance. Salivation was assessed by means of 
severity and frequency scales. The mean secretion of saliva 
in the toxin-treated group was significantly lower than in 
the placebo series, and this effect persisted for about three 
months. After injecting 30 U of Botox® per gland in 15 
patients (15), quantitative sialometry showed that intrapa-
rotid injections under ultrasound guidance (n=8) improved 
sialorrhea to a greater degree than injections performed 
on a blind basis (n=7). Salivation was reduced during 2-6 
months (mean 4.4 ± 1.2), though two patients experienced 
slight xerostomia for one month.
BOTULINUM TOXIN IN PATIENTS WITH DI-
FFErENT NEUrOLOGICAL DISOrDErS
Bhatia et al. (22) injected TBA via the subcutaneous route 
into the parotid glands of four patients, over the mandibular 
angle at the posterior margin of the masseter muscle, in-
volving a dose of 20 U of Dysport®. The exception was 
a patient with motor neuron disease, who received half  of 
the aforementioned dose, due to the risk of worsening the 
dysphagia. A beneficial effect was observed that persisted 
for a period of between 6 weeks and four months, though 
it must be stressed that salivation in these cases was subjec-
tively assessed. Adverse effects such as chewing difficulty, 
dry mouth and worsening of the pre-existing dysphagia were 
reported. Using the same intraparotid technique, though 
without undesirable adverse effects, a dose of  150 U of 
Dysport® per gland was injected in a patient with central 
degenerative neuropathy (23), resulting in subjective im-
provement that lasted 6 months. Likewise with intraparotid 
injections, though involving two sessions spaced two weeks 
apart, 20-40 U of Botox® were administered, followed by 
50-60 U of the toxin in three patients with chronic neurolo-
gical disease: motor neuron disease, Parkinson’s disease and 
pontine infarction (25). The minimum duration of the effect 
was three months following assessment based on the sialo-
rrhea intensity and severity scale (29). The efficacy of the 
intraparotid injection of three different doses of TBA versus 
the administration of placebo in patients with neurological 
disease has also been confirmed, resulting in a significant 
reduction in drooling among the patients injected with 75 U 
of Dysport® into each parotid gland - such administration 
being repeated three months later (26).
BOTULINUM TOXIN IN PATIENTS WITH 
OTHEr PATHOLOGIES
With the simultaneous infiltration of  the parotid and 
submaxillary glands, involving total doses of 50-65 U of 
Botox®, different studies (9,19,21,27) in patients with a 
range of disorders (neurodegenerative diseases, idiopathic 
hypersalivation, head and neck carcinomas, etc.) have 
reported improvements in excessive salivation during an 
average period of  about three months, without adverse 
effects. Likewise, a beneficial effect upon sialorrhea has been 
reported in three patients (20) with persistent pharyngo-cu-
taneous fistulas after total laryngectomy. A beneficial effect 
lasting about two months was observed, though assessment 
was subjective.
SALIVArY GLAND INJECTION OF TBA
Primary sialorrhea is a relatively rare condition, while 
hypersalivation secondary to dysphagia or swallowing co-
ordination problems is much more common in the context 
of neurological disease. This symptom has been treated by 
different authors based on TBA injection into the salivary 
glands.
Of the 21 articles found in the literature search involving 
TBA injection in humans, 15 corresponded to prospective 
case studies, while four were case-control studies (11,13,15, 
26), and two articles contributed a single clinical case each 
(17,23).
- Type of anesthesia
The type of anesthesia used ranged from topical local anes-
thetic cream (8,10) to general anesthesia (6,11), while some 
authors required no local anesthesia (9). The rest of studies 
did not specify the type of anesthesia used.
- Needle caliber
Regarding the needle caliber used for infiltration of the 
gland parenchyma, important variability has been obser-
ved - the caliber ranging from 21G (23) to 22G (18), 25G 
(6,11,22), 26G (14), 27G (16,25), 29G (13,17), and 30G 
(8,15,26).
- Salivary glands injected
Most authors injected the toxin into the parotid glands, 
possibly because the latter are superficial and thus are more 
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easily accessible for TBA injection, and because of the im-
portant contribution of these glands to total saliva output. 
Other investigators such as Jonguerius et al. (6,11) perform 
injection in the submaxillary glands, on the grounds that 
this avoids reduction of parotid output while the patient 
eats and drinks. Giess et al. (16) only injected TBA into the 
submaxillary glands in those cases where injection into the 
parotid glands proved scantly effective. Suskind and Tilton 
(10) in turn differentiated two groups of patients on deciding 
injection: one group was injected into the submaxillary 
glands, and the other into both the submaxillary and the 
parotid glands. No differences in the reduction of drooling 
were recorded between the two groups.
In the parotid gland, the number of injection points ranged 
from one (8,13,17) to two (10,12,15,18,26), three (cranial, 
medial and caudad)(16), and even 10 points (20). In the 
submaxillary gland, three (11,20), two (6) and one injection 
point have been used (10,18).
- TBA dose
A broad TBA dose range has been used, specifically from 
10-100 U of Botox® or 20-300 U of Dysport® per patient. 
The safe maximum dose is not known, though it could be 
very low in some situations - particularly in patients with 
amyotrophic lateral sclerosis, who may be especially sensitive 
to the toxin. Likewise, the effect of repeated injections of 
TBA over time are not known, and it is not clear whether 
antibodies are produced as a result.
- Adverse effects
Adverse effects are not particularly frequent; however, 
some patients have experienced xerostomia, dysphagia and 
chewing difficulties. Recurrent mandibular luxation has 
even been reported in a patient with amyotrophic lateral 
sclerosis (17).
- Methods for the evaluation of treatment response
The sialorrhea intensity and frequency scale (29), used by 
authors such as Manzini et al. (14) and Carod (25), is an 
objective and inexpensive tool for assessing patient response 
to treatment. Other procedures used for the same purpose 
include the number of napkins used daily to contain exces-
sive saliva production (8, 16), and even salivary gland gam-
magraphy (16). The importance of objective methods is that 
they seem to be more sensitive in detecting a reduction in 
sialorrhea or drooling than purely subjective assessments.
- Ultrasound guidance
One-half  of the reviewed studies made use of ultrasound 
guidance for intraglandular injection. Blind puncture of the 
superficial lobe of the parotid gland allows the infiltration 
of TBA without too many technical complications, since the 
structure is relative superficial. Infiltration of the submaxi-
llary gland is somewhat more difficult, since it is normally 
not palpable. This makes ultrasound advisable to identify 
the gland structure (21). In addition, ultrasound guidance 
makes it possible to avoid accidental damage to other ana-
tomical structures - specifically the facial nerve in the case 
of injection into the parotid gland, or the facial vessels in 
the case of the submaxillary gland. Ultrasound allows safe 
application to the gland parenchyma even under unfavorable 
anatomical conditions, as in patients with postoperative 
scar tissues. Moreover, it facilitates the detection of possible 
gland tissue alterations after injection.
- Duration of the effect therapeutic
As to the duration of the effect after the application of 
TBA, marked differences have been observed. In effect, the 
recorded duration ranged from one and a half  months (13) 
to as long as 6 months (23).
CONCLUSIONS
The injection of TBA into the salivary glands may be a valid 
treatment option in patients with sialorrhea, since it is able 
to improve quality of life. However, it is important to take 
into account that the duration of the therapeutic effect is 
limited in time, generally lasting a few months. Although 
TBA constitutes safe and effective treatment for secretory 
disorders such as focal axillary and palmar hyperhidrosis, 
the patient inclusion criteria differ among studies - many 
of which moreover involve samples that are too small to 
allow the obtainment of statistically significant results. In 
addition, most of these studies lack blinding, randomiza-
tion or comparison versus placebo. Controlled studies are 
therefore needed to assess the maximum doses, location of 
the most effective and safe injection points, and definition 
of the number of TBA infiltrations required in neurological 
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